Media stories about PetMed Express (NASDAQ:PETS) have been trending positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PetMed Express earned a daily sentiment score of 0.30 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 74 out of 100, meaning that recent press coverage is likely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- PetMed Express, Inc. (NASDAQ:PETS) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- PetMed Express D/B/A 1-800-PetMeds to Announce Its First Quarter Financial … (globenewswire.com)
- PetMed Express D/B/A 1-800-PetMeds to Announce Its First Quarter Financial Results on July 24, 2017 (finance.yahoo.com)
- Head to Head Contrast: Rite Aid Corporation (RAD) vs. PetMed Express (NASDAQ:PETS) (americanbankingnews.com)
- Technical Reports on Drug Delivery Equities — PetMed Express, Adamis Pharma, Delcath Systems, and Alkermes (bizjournals.com)
Shares of PetMed Express (NASDAQ PETS) opened at 39.28 on Tuesday. The company’s 50-day moving average is $36.58 and its 200-day moving average is $25.68. The stock has a market capitalization of $797.11 million, a PE ratio of 33.57 and a beta of 0.95. PetMed Express has a 12 month low of $18.90 and a 12 month high of $41.73.
PetMed Express (NASDAQ:PETS) last issued its quarterly earnings data on Monday, May 8th. The company reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.11. The company had revenue of $63.03 million for the quarter, compared to analyst estimates of $56.53 million. PetMed Express had a net margin of 9.56% and a return on equity of 26.69%. The company’s revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.27 earnings per share. Equities research analysts expect that PetMed Express will post $1.29 earnings per share for the current fiscal year.
A number of analysts have recently commented on PETS shares. Zacks Investment Research upgraded PetMed Express from a “sell” rating to a “hold” rating in a report on Tuesday, March 28th. Craig Hallum downgraded PetMed Express from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th.
TRADEMARK VIOLATION WARNING: “PetMed Express (NASDAQ:PETS) Receiving Favorable Press Coverage, Report Finds” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/07/18/positive-press-coverage-likely-to-affect-petmed-express-pets-share-price-updated-updated-updated.html.
In other PetMed Express news, Director Gian Fulgoni sold 35,000 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $32.22, for a total transaction of $1,127,700.00. Following the sale, the director now directly owns 68,400 shares in the company, valued at $2,203,848. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Bruce S. Rosenbloom sold 1,500 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $24.00, for a total transaction of $36,000.00. Following the sale, the insider now owns 34,267 shares in the company, valued at $822,408. The disclosure for this sale can be found here. Insiders sold 50,500 shares of company stock worth $1,583,300 over the last three months. Insiders own 4.00% of the company’s stock.
About PetMed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.